Conf de Theo Thepen: Immunotoxins as therapeutic alternative in leishmaniasis

Dr. Theo Thepen, do Fraunhofer Institute (Aachen), colaborador internacional do LIMI, proferirá conferência no Centro de Pesquisas Gonçalo Moniz (CPqGM; FIOCRUZ-Bahia) intitulada:

"Immunotoxins as therapeutic alternative in leishmaniasis"

A conferência será dia 20 de julho (3a-f) às 14’00, no Auditório do CPqGM.

Veja alguns dados do Dr. Thepen, da sua página no Fraunhofer Institute:

Description

University Training:
01-08-1980 - 12-12-1987
Medical Biology, Vrije Universiteit, Amsterdam, the Netherlands
PhD: 01-12-1987 - 25-01-1992, Department of Cell biology/Immunology, Vrije Universiteit, Amsterdam, the Netherlands. Title PhD thesis: 'Regulation of Pulmonary Immune responses by Alveolar Macrophages'. 

Research Fellow:
01-04-1989 - 15-10-1989 (Travel grant VU)
01-11-1990 - 01-04-1991 (Travel grant NWO), The Department of Immunology, Western Australian Research Institute of Child Health, Princess Margaret Children’s Hospital, Perth, Western Australia 

Relevant work experience:
Postdoc 25-01-1992 - 01-07-1992, Department of Cell biology/Immunology, Vrije Universiteit, Amsterdam.
Postdoc 01-07-1992 - 31-03-1994, Dep. Dermatology /Allergology, Academic Hospital Utrecht.
University Lecturer / Assistant Professor: 01-04-1994 - 31-06-1997, Dep.Dermatology/Allergology, Academic Hospital Utrecht.
Senior Scientist: 01-04-1997 - 31-06-2002, Department of Immunotherapy, University Medical Centre Utrecht / Medarex Europe BV
Principal Scientist: 01-07-2002 - 31-06-2003, Department of Pharmacy, Utrecht University, Utrecht /Medarex Inc, Annandale, USA.
Principal Scientist: 01-07-2003 - present, Fraunhofer IME, Aachen

Projects:

• Accelerated Drug Development (IMHOTEP)
• Immunochemistry
• Imaging and Molecular imaging
• Animal models

Veja as 10 publicações mais recentes do Dr. Thepen, no PubMed:

Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein.

Kampmeier F, Niesen J, Koers A, Ribbert M, Brecht A, Fischer R, Kießling F, Barth S, Thepen T.

Eur J Nucl Med Mol Imaging. 2010 May 7. [Epub ahead of print]

Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.

Ribbert T, Thepen T, Tur MK, Fischer R, Huhn M, Barth S.

Br J Dermatol. 2010 Apr 26. [Epub ahead of print]

Fcgamma receptor 1 (CD64), a target beyond cancer.

Thepen T, Huhn M, Melmer G, Tur MK, Barth S.

Curr Pharm Des. 2009;15(23):2712-8. Review.

Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cells.

Ranft K, Thepen T, Fischer R, Barth S, Stöcker M.

Cancer Lett. 2009 Sep 18;282(2):187-94. Epub 2009 Apr 3.

Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.

Stahnke B, Thepen T, Stöcker M, Rosinke R, Jost E, Fischer R, Tur MK, Barth S.

Mol Cancer Ther. 2008 Sep;7(9):2924-32.

Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin.

Nachreiner T, Kampmeier F, Thepen T, Fischer R, Barth S, Stöcker M.

J Neuroimmunol. 2008 Mar;195(1-2):28-35. Epub 2008 Feb 15.

CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model.

van Vuuren AJ, van Roon JA, Walraven V, Stuij I, Harmsen MC, McLaughlin PM, van de Winkel JG, Thepen T.

J Immunol. 2006 May 15;176(10):5833-8.

Recombinant soluble human Fcgamma receptor I with picomolar affinity for immunoglobulin G.

Paetz A, Sack M, Thepen T, Tur MK, Bruell D, Finnern R, Fischer R, Barth S.

Biochem Biophys Res Commun. 2005 Dec 30;338(4):1811-7. Epub 2005 Nov 2.

Fc gamma RIIB regulates nasal and oral tolerance: a role for dendritic cells.

Samsom JN, van Berkel LA, van Helvoort JM, Unger WW, Jansen W, Thepen T, Mebius RE, Verbeek SS, Kraal G.

J Immunol. 2005 May 1;174(9):5279-87.

Macrophages play a dual role during pulmonary tuberculosis in mice.

Leemans JC, Thepen T, Weijer S, Florquin S, van Rooijen N, van de Winkel JG, van der Poll T.

J Infect Dis. 2005 Jan 1;191(1):65-74. Epub 2004 Nov 29.